Eric Singhi, Thoracic Medical Oncologist at MD Anderson Cancer Center, shared a post on LinkedIn:
“Top 5 gaps in EGFR+ lung cancer today
- Who really needs combo therapy?
- How do we choose b/w frontline combos?
- Is TKI monotherapy still enough?
- Can we reduce toxicity w/o sacrificing efficacy?
- Should we treat earlier to improve long-term outcomes?”
You can also read:
